Clinical Trials Directory

Trials / Completed

CompletedNCT01809275

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
68 (actual)
Sponsor
Qu Biologics Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety profile and to obtain an indication as to the therapeutic effect of QBECO induction treatment on clinical improvement in moderate to severe Crohn's Disease.

Conditions

Interventions

TypeNameDescription
DRUGQBECO
DRUGPlacebo

Timeline

Start date
2013-03-01
Primary completion
2016-02-01
Completion
2016-07-01
First posted
2013-03-12
Last updated
2016-08-23

Locations

4 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01809275. Inclusion in this directory is not an endorsement.

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease (NCT01809275) · Clinical Trials Directory